New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
11:01 EDTNRF, ESI, KBR, NVS, AFFYHigh option volume stocks: NVS ESI AFFY KBR NRF
News For NVS;ESI;AFFY;KBR;NRF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
June 24, 2015
14:40 EDTESIITT Educational responds to Rohit Chopra letter
Nicole Elam, vice president of government relations and external affairs for ITT Educational Services, issued the following statement in response to a letter from Rohit Chopra, former student loan ombudsman for the Consumer Financial Protection Bureau, to investors dated June 24, 2015: "Putting aside the troubling fact that Mr. Rohit Chopra is attempting to impact investors of a publicly traded company with information he received while in an official capacity at a U.S. governmental agency, his letter is a perfect example of the myopic view pervading some in D.C. regarding taxpaying educational institutions. The fact that he would write such a letter to investors days after leaving the Consumer Financial Protection Bureau trumpeting mere allegations against the company demonstrates a personal bias against our institutions and an unwillingness to allow for due process to work, the cornerstone of the U.S. legal system. Allegations are not facts and we think our investors will not take action based on simple assertions from someone with an ideological axe to grind."
10:40 EDTESIITT Educational says CSAAVE suspension put on hold by judge
ITT Educational issued a public notice, dated June 23, stating that the California State Approving Agency for Veterans Education, a division of the California Department of Veterans Affairs, previously issued a suspension of approval to all 15 California institutions owned and operated by ITT Educational, doing business as ITT Technical Institute. "On June 23, 2015, the Honorable Judge William Claster of the Orange County Superior Court issued an order staying CSAAVE’s suspension of approval of ITT’s courses for enrollment by veteran students, pending the Court’s adjudication of ITT’s petition for peremptory writ of mandate on or after August 21, 2015. While this stay is in effect, CSAAVE’s suspension of ITT’s courses for enrollment by veteran students is lifted...While the suspension is stayed, veterans may enroll at ITT," the company stated in its notice. Reference Link
09:01 EDTNRFNorthstar Realty management to meet with Deutsche Bank
Subscribe for More Information
05:47 EDTNRFStocks with implied volatility movement; NRF DDD
Subscribe for More Information
June 23, 2015
07:29 EDTNRFNorthstar Realty management to meet with Deutsche Bank
Subscribe for More Information
June 18, 2015
17:05 EDTNVSNovartis announces U.S. launch of Glatopa
Sandoz, a Novartis (NVS) company, announced the U.S. launch of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy.
11:54 EDTNVSAppeals court invalidates Teva patent claim related to Copaxone
Subscribe for More Information
06:57 EDTNVSMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
June 16, 2015
10:29 EDTNVSGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
05:56 EDTESIStocks with implied volatility below IV index mean; KORS ESI
Subscribe for More Information
05:45 EDTNVSNovartis to host two day investor event
Subscribe for More Information
05:40 EDTNVSNovartis division Alcon receives CE Mark for AcrySof IQ PanOptix trifocal IOL
Alcon, a division of Novartis, has received European CE Mark for its AcrySof IQ PanOptix trifocal intraocular lens, or IOL, for patients undergoing cataract surgery who elect to address their near, intermediate, and distance vision needs with a single lens. The AcrySof IQ PanOptix trifocal IOL is an important addition to Alcon's broad portfolio of intraocular lenses for cataract patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use